Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK117 + docetaxel
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AK117 + docetaxel is an investigational combination therapy consisting of AK117, a monoclonal antibody targeting CD47, and docetaxel, a chemotherapeutic agent that stabilizes microtubules and inhibits cell division. AK117 is designed to block the CD47-SIRPα interaction, thereby enabling macrophage-mediated phagocytosis of tumor cells. Docetaxel disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. This combination is being evaluated for its potential to provide synergistic antitumor effects, particularly in the treatment of prostate cancer and potentially other solid tumors.
- Brand names
- TaxotereDocefrezACT DOCEtaxelTaro-DOCEtaxel
- Other names
- AK117AK-117AK 117docetaxel
02
Targets
MicrotubuleCD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on AK117 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK117 + docetaxel.